Insilico announces Pandomics, an AI-powered hypothesis generation engine that interprets OMICS and text-based data for the discovery and analysis of new therapeutic targets.
Insilico is busy, busy, busy. In just a few months it has partnered with Arctoris in a robotics/AI partnership, spun-out Deep Longevity (which then launched Young.AI, having previously just been acquired by Regent Pacific) and teamed up with Intel for a new COVIDomic platform.
Longevity.Technology: Insilico Medicine began work on an engine for target identification back in 2014. Since then, it has had several successful partnering initiatives with pharma and research organisations as well as its own drug development programmes.
Pandomics aims to be bamboozingly successful as the go-to platform for biologists and clinicians, who will be able to use a variety of OMICS datasets, analysing, interpreting and visualising data in order to classify patient cohorts more accurately. Leveraging this potent AI to discover and develop drugs that target aging could make significant improvements to Longevity outcomes.
Today Insilico announced Pandomics, a part of the Pharma.ai platform which is designed to boost pharmaceutical target and drug discovery pipelines.
“We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics …”
Research biologists and clinicians will be able to use Pandomics to perform OMICS data analytics and interpretation without requiring any prior knowledge of computational biology or bioinformatics, Insilico said. In addition, drug target identification and biomarker development specialists will be able to use the AI platform to generate hypotheses and assess repositioning strategies.
Pandomics targets metrics and is able to assemble publication data on a gene, including patents, news, publications and articles, as well as showing whether these instances are increasing or decreasing, indicating whether the scientific community is saturated with information, or whether there are areas still left to explore. The contexualised knowledge links genes and diseases and, according to today’s press briefing, is an “evolution of AI tools – a pandomics revolution.”
“At Insilico, we have developed a platform that hands the power of bioinformatics over to the researcher’s hands. Biologists, clinicians and therapeutic target specialists, will gain a wide range of novel visual ways to interpret biological data. When designing the tool, we focused on storytelling in data analysis and providing guidance for each step.” said Alexey Dubovenko, Product Director for Pandomics at Insilico Medicine.
“We recently used parts of the Pandomics platform in combination with Chemistry42, our generative chemistry platform and inClinico, our clinical trials prediction platform, to demonstrate that we can go from the nomination of disease of interest to novel disease targets, to compounds that are ready to enter IND-enabling studies in record time,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
He added: “We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics. We are very happy to put this system into the hands of research scientists, drug discovery and development experts, and medical doctors interested in research and academic publishing.”